BIOMAT Database Logo BIOMAT Database Logo

[Immunological effectiveness of a dried group-A meningococcal polysaccharide vaccine]. 1984

A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina

The immunological effectiveness of dried group A meningococcal polysaccharide vaccine, developed at the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, for children aged 5-14 years was studied. The intensiveness of the immune response of children to 0.5 ml of the vaccine introduced in a single injection was evaluated by a rise in the level of agglutinating antibodies to group A meningococcal polysaccharide in the sera of the vaccinees 3-4 weeks after immunization with the following optimum doses: 25 micrograms for children aged 5-8 years, 50 micrograms for children aged 9-13 years and 75 micrograms for children aged 14 years and over. The vaccine was shown to be highly immunogenic. Antibodies to group A meningococcal polysaccharide were identified as IgM. These antibodies in a titer of 1:40 and higher could be detected in 90% of the vaccinated children in the younger age group, 7 months after immunization.

UI MeSH Term Description Entries
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies

Related Publications

A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland.
January 1978, Scandinavian journal of infectious diseases,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
[Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
June 2008, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
Prevention of meningococcal disease by group C polysaccharide vaccine.
February 1970, The New England journal of medicine,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
[Reactogenicity of a group A and C meningococcal polysaccharide bivalent vaccine].
July 1986, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
[Safety, reactogenicity and immunological activity of a group A meningococcal polysaccharide vaccine for children 1-4 years old].
May 1987, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
Molecular shape and immunogenicity of meningococcal polysaccharide group A conjugate vaccine.
October 2015, Vaccine,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
[Evaluation on the safety of a group A + C meningococcal polysaccharide vaccine].
May 2007, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
[Meningococcal carrier state in collectives vaccinated with group A polysaccharide vaccine].
March 1978, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate.
May 1983, The Journal of infection,
A P Alliluev, and O V Kotel'nikova, and T F Chernyshova, and T A Skirda, and V I Kuvakina
[Efficacy of the meningococcal vaccine from Group C capsular polysaccharide].
January 1997, Revista espanola de salud publica,
Copied contents to your clipboard!